Corporate$ARCT4:06 PM ET

Arcturus Therapeutics: ARCT-810 Safe, Well Tolerated, Encouraging Urea Cycle Biomarker Activity in Phase 2

By BORSA NewsroomPublished Sep 23, 2026, 4:06 PM EDTUpdated Sep 25, 2026, 11:53 AM EDT

Arcturus Therapeutics announced that its Phase 2 study of ARCT-810 showed the drug is generally safe and well tolerated, with encouraging activity across key urea cycle biomarkers.

Sentimentneutral 50

Neutral · 50 of 100

Impact40

low · stays off the top drivers

Confidence90%

high confidence · single wire

Eventdeveloping

v1 · alerts feed only

WHAT WE KNOW

Phase 2 study of ARCT-810 is ongoing
Drug is generally safe and well tolerated